Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights

Biotech SG&A Expenses: Blueprint vs. Ligand

__timestampBlueprint Medicines CorporationLigand Pharmaceuticals Incorporated
Wednesday, January 1, 2014789000022570000
Thursday, January 1, 20151445600024378000
Friday, January 1, 20161921800026621000
Sunday, January 1, 20172798600028653000
Monday, January 1, 20184792800037734000
Tuesday, January 1, 20199638800041884000
Wednesday, January 1, 202015774300064435000
Friday, January 1, 202119529300057483000
Saturday, January 1, 202223737400070062000
Sunday, January 1, 202329514100052790000
Monday, January 1, 2024359272000
Loading chart...

Data in motion

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for sustaining growth and innovation. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, Blueprint Medicines has seen a staggering increase in SG&A expenses, growing by approximately 3,640%, from $7.89 million in 2014 to $295 million in 2023. In contrast, Ligand Pharmaceuticals experienced a more modest increase of about 134%, from $22.57 million to $52.79 million.

Key Insights

  • Blueprint Medicines: The rapid rise in expenses reflects its aggressive expansion and investment in research and development.
  • Ligand Pharmaceuticals: The steadier growth in expenses suggests a more conservative approach, focusing on strategic partnerships and licensing.

Understanding these trends provides valuable insights into each company's strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025